<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03597997</url>
  </required_header>
  <id_info>
    <org_study_id>UW18-176</org_study_id>
    <nct_id>NCT03597997</nct_id>
  </id_info>
  <brief_title>Effects of TIVA With Propofol Versus Inhalational Anaesthesia on Postoperative Pain After Hepatectomy</brief_title>
  <official_title>Effects of Intraoperative Total Intravenous Anaesthesia (TIVA) With Propofol Versus Inhalational Anaesthesia on Postoperative Pain After Hepatectomy: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Propofol is a commonly used intravenous anaesthetic drugs both for induction and maintenance
      of general anaesthesia. Advantages of total intravenous anaesthesia (TIVA) with propofol
      include reduced nausea and vomiting, reduced atmospheric pollution, and better wake up
      profile. But the need for a reliable intravenous access, specialized pumps, pain on injection
      and potential concerns regarding awareness are potential disadvantages of TIVA propofol.

      Results from clinical trials have not been consistent. Some randomized trials have shown
      improved analgesia with TIVA propofol, and some reported no significant difference. A
      meta-analysis found that propofol was associated with a statistically significant reduction
      pain scores 24 hours after surgery. However, the clinical effect size was small. Therefore,
      the usefulness of propofol as an analgesic adjunct is still inconclusive.

      Whether TIVA propofol is useful in providing significant postoperative analgesia may be
      influenced by the type of surgery and accompanying analgesic regime. This agrees with the
      concept of procedure specific analgesia. Liver surgery produces moderate to severe pain as a
      result of an upper abdominal incision. Pain control can be difficult due to concerns with
      epidural analgesia in patients with potential clotting abnormalities and the effect of
      analgesic metabolism as a in patients with liver dysfunction. Results from our retrospective
      study showed that TIVA propofol was associated with reduced pain scores with coughing on
      postoperative days 1 and 2, and also reduced opioid consumption when compared with
      sevoflurane after liver surgery.

      In this study, the investigators plan to conduct a randomized controlled trial to further
      determine whether TIVA propofol reduces acute postoperative pain and opioid consumption after
      hepatectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      * Preoperative care

      Assessment will be done at the preadmission clinic or at the general ward. Fasting for
      patients will start at midnight before operation. Sedative premedication will not be
      prescribed.

      * Anaesthesia and intraoperative care

      = Group S (sevoflurane) - Patients from group S will be anaesthetized by inhalational
      anaesthesia using sevoflurane, according to the following protocol:

      On arrival to the operation theatre, a 20 or 22 gauge intravenous cannula will be inserted.
      Standard monitoring with pulse oximeter, non-invasive blood pressure, and three lead
      electrocardiogram will be applied prior to induction. Non-invasive blood pressure will be
      checked at least every 5 minutes throughout the operation.

      Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg
      will be used intravenously (IV) for induction of general anaesthesia. Intubation would be
      performed after induction of general anaesthesia. General anaesthesia monitoring will be
      used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2
      will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be
      titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between
      0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic
      parameters. Muscle relaxants can be given during the operation as required.

      Intravenous phenylephrine, ephedrine or fluid administration with colloid or crystalloid will
      be given at the discretion of the anaesthesiologist for management of hypotension.
      Hypertension or tachycardia will be managed by titrating the remifentanil infusion up to
      0.2mcg/kg/min or sevoflurane up to 1.5 MAC. Intravenous anti hypertensive agents such as beta
      blockers (eg. esmolol, labetolol), hydralazine, glyceryl trinitrate, and phentolamine can be
      given if hypertension persists.

      Thermal blanket will be used with the aim of keeping a core temperature of 35.5-37.5 degrees
      Celsius. Ondansetron 4mg IV will be given 30 minutes before end of surgery.

      Sevoflurane and remifentanil infusion will be switched off at the end of the procedure.
      Reversal of muscle relaxation can be obtained if required with neostigmine 50mcg/kg IV and
      atropine 20mcg/kg IV after the operation. Patients will subsequently be transferred to the
      post anaesthetic care unit (PACU) for monitoring for at least 30 minutes.

      = Group P (propofol) - Patients in group P will be anaesthetized using total intravenous
      propofol, according to the following protocol:

      Monitoring and other anaesthetic procedures including the management of hypertension and
      hypotension will be the same as group S. The only difference is that induction and
      maintenance of general anaesthesia will be conducted using total intravenous infusion of
      propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2
      of 30-50%.

      Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will
      be used for induction and maintenance of general anaesthesia. Level of anaesthesia will be
      titrated to produce a BIS value of between 40-60. During induction of general anaesthesia,
      remifentanil 0.5-1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be given
      intravenously (IV). Remifentanil will be infused at a rate of between 0.1-0.2mcg/kg/min
      during maintenance of anaesthesia.

      * Analgesic modalities and pain assessment

      Both groups (Groups S and P)

      Morphine sulphate at a bolus dose of 0.1mg/kg will be given intravenously before skin
      incision. Additional 0.1mg/kg of morphine sulphate can be given in divided doses when the
      surgery has continued for more than 2 hours at the discretion of the anaesthetist. Ketamine
      0.5mg/kg intravenously will be given before skin incision. Patients will receive local wound
      infiltration with up to 2mg/kg of levobupivicaine during wound closure.

      Resting pain scores will be checked every 5 minutes in the post anaesthetic care unit. 2mg
      boluses of intravenous morphine sulphate will be given every 5 minutes until the NRS pain
      score is less than 4/10. Respiratory rate, oxygen saturation, Ramsay sedation scores, blood
      pressure and heart rate will be monitored every 5 minutes while the patient is in the post
      anaesthetic care unit. A PCA morphine machine will be connected to the patient once the NRS
      pain score is less than 4/10. The PCA morphine machine will be set to give 1mg of intravenous
      morphine sulphate with each patient demand, and lockout duration of 5 minutes will be set.
      Maximum dose limit will be 0.1mg/kg of morphine sulphate per hour and basal infusion will not
      be given.

      When the patient resumes fluid diet in the ward on postoperative day 0, regular oral
      dihydrocodeine will be prescribed at a dose of 30mg tds for two days. Afterwards,
      dihydrocodeine will be given as needed. Breakthrough pain will be treated by
      intramuscular/subcutaneous morphine 0.1mg/kg every 4 hours as needed starting from
      postoperative day 0.

      Respiratory rate, oxygen saturation, sedation scores will be monitored every hour while
      patient is using PCA morphine. Blood pressure and heart rate will be measured every 4 hours.
      Pain related parameters like the numerical rating scales (NRS) pain scores at rest and during
      cough, cumulative PCA morphine doses and number of PCA demands/goods delivered, and side
      effects will also be recorded very 4 hours. Anaesthesiologists will assess patients every day
      to determine the adequacy of analgesia.

      PCA morphine will be given for at least 2 days. PCA morphine will be stopped on postoperative
      day 2 if NRS pain scores during cough is less than 4/10 and morphine consumption is low. If
      PCA morphine consumption is high or NRS pain scores during cough is equal or greater than 4,
      PCA morphine will be continued. Assessment will be performed everyday. An NRS pain score that
      is 4 or higher during coughing on postoperative day 5 will require an evaluation for
      complications. The patient will be further managed at the discretion of the
      anaesthesiologist. After discontinuation of PCA morphine, NRS pain scores (at rest and with
      coughing) and the dose and frequency of rescue analgesia used will be recorded daily until
      patient discharge.

      NRS pain score and satisfaction with analgesia (scored from 0-10, where 0 is the least
      satisfaction and 10 most satisfaction) will be obtained.

      Quality of recovery 9 (QoR-9) is measured at 24h and 72h after surgery. The attending surgeon
      will determine final hospital discharge

      * A brief home telephone interview will be conducted at 3 and 6 months to assess the
      incidence of chronic pain. The severity of pain, if present, would be recorded using NRS
      (0-10) at rest and with coughing. Other information that will be obtained at 3 and 6 months
      after surgery include HRQOL obtained with the Chinese-HK version of the SF12v2- health survey
      and psychological condition will be assessed with the Hospital Anxiety and Depression Scale
      (HADS) questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients in one group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane. The patients in the second group (P) will be anaesthetized using total intravenous propofol.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Patients will not be aware of the type of anaesthesia they will receive. A separate blinded investigator will assess the patients after the operation. The anaesthetist providing general anaesthesia will be aware of the allocation, but s/he will not be involved in data collection.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain assessed by numercial rating scales (NRS) pain scores</measure>
    <time_frame>at postoperative day 1</time_frame>
    <description>NRS pain scores (from 0-10, where 0 is the least satisfaction and 10 most satisfaction) will be recorded at rest and with coughing everyday.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCA morphin consumption</measure>
    <time_frame>from postoperative day 0 until postoperative day 5</time_frame>
    <description>Cumulative PCA morphine doses (in mg) will be recorded daily based on medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dihydrocodeine use</measure>
    <time_frame>from postoperative day 0 until postoperative day 5</time_frame>
    <description>Frequency of dihydrocodeine use (i.e. how many times per day) will be recorded daily according to medical record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of analgesics</measure>
    <time_frame>from postoperative day 0 until postoperative day 5</time_frame>
    <description>Pruritus, dizziness, nausea, vomiting, wound infection, urinary retention, confusion, constipation will be recorded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in group (P) will be anaesthetized using total intravenous propofol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group S</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients in group (S) will be anaesthetized by inhalational anaesthesia using sevoflurane.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Target controlled infusion (TCI) with modified Marsh effect site model (Fresenius Kabi) will be used for induction and maintenance of general anaesthesia. Monitoring and other anaesthetic procedures including the management of hypertension and hypotension in group P will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Oxygen and air would be given to provide a FiO2 of 30-50%.</description>
    <arm_group_label>Group P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>Propofol 1.5-3mg/kg, remifentanil 1mcg/kg, and rocuronium 0.6-1mg/kg or atracurium 0.5mg/kg will be used intravenously for induction of general anaesthesia. Intubation would be performed after induction of general anaesthesia. General anaesthesia monitoring will be used. Sevoflurane, air and oxygen will be used for maintenance of general anaesthesia. FiO2 will be kept between 35-50%. BIS monitoring will be applied and level of anaesthetia will be titrated to maintain a BIS value of between 40-60. Intravenous remifentanil infusion between 0.1-0.2 mcg/kg/min will be given and this will be titrated to provide optimal haemodynamic parameters.</description>
    <arm_group_label>Group S</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I to III

          -  Scheduled for elective hepatectomy (left or right hepatectomy, segmentectomy, or wedge
             resection)

        Exclusion Criteria:

          -  Known drug allergy to propofol, opioids, non-steroidal anti-inflammatory drugs
             (NSAIDs) including COX-2 inhibitors, paracetamol, ketamine

          -  Alcohol or drug abuse

          -  Impaired renal function, defined as preoperative serum creatinine level over 120Âµmol/L

          -  Impaired or retarded mental state

          -  BMI &gt; 35kg/m2

          -  History of chronic pain

          -  Pregnancy

          -  Local infection

          -  History of psychosis, delirium

          -  Chronic opioid user

          -  Patient refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley SC Wong, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stanley SC Wong, MBBS</last_name>
    <phone>(852)22553303</phone>
    <email>wongstan@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley SC Wong, MBBS</last_name>
      <phone>(852)22553303</phone>
      <email>wongstan@hku.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>May 16, 2019</last_update_submitted>
  <last_update_submitted_qc>May 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Wong Sau Ching Stanley</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Postoperative pain</keyword>
  <keyword>Total intravenous anaesthesia</keyword>
  <keyword>TIVA</keyword>
  <keyword>Propofol</keyword>
  <keyword>Hepatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

